By increasing the miR-34a transcription, JP-1 might enhance the anticancer effects of cisplatin and radiotherapy.
The effects of JP-1 on the activation of p53/miR-34a axis shown in this study imply its potential in CSC elimination, which might contribute to the clinical benefit observed in patients.
Based on the effects of JP-1 shown in this study, modulation of PDL1 might also be part of the JP-1-activated p53/miR-34a tumor suppressor axis.
Our results demonstrate that JP-1 activates p53 and its downstream targets such as p21, BAX, and miR-34a in A549 LADC cells.
Caption: Figure 1: JP-1 inhibits the proliferation and colony formation of A549 cells but only slightly affects the growth of HS68 primary fibroblast cells.
Caption: Figure 2: Representative flow cytometry histograms of A549 cells stained with PI after treatment with JP-1 for 48 h.
Caption: Figure 3: Effects of JP-1 on the AMPK/mTOR and CDK6/pRb cascades in A549 cells.
Caption: Figure 4: JP-1 induces p53 and its downstream p21 and BAX proteins accompanied by the activation of PARP and caspases in A549 cells.
Caption: Figure 5: JP-1 induces the transcription of miR-34a and decreases its downstream targets required for proliferation and apoptosis resistance in A549 cells.